Heterocyclic amide compounds as protein kinase inhibitors
    52.
    发明授权
    Heterocyclic amide compounds as protein kinase inhibitors 有权
    杂环酰胺化合物作为蛋白激酶抑制剂

    公开(公告)号:US08669259B2

    公开(公告)日:2014-03-11

    申请号:US13391402

    申请日:2010-08-19

    IPC分类号: A61K31/496 C07D401/04

    摘要: The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating or preventing a disease or disorder related to the activity of a protein kinase, in particular, a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal infection.

    摘要翻译: 本发明涉及式(I)的杂环酰胺衍生物:式(I),其中变量如说明书中所定义。 本发明还涉及包含式(I)的所述杂环酰胺衍生物和式(I)的所述杂环酰胺衍生物用于治疗或预防与蛋白激酶活性相关的疾病或病症的方法的组合物, 增殖性疾病,抗增殖性疾病,炎症,关节炎,神经性或神经变性疾病,心血管疾病,脱发,神经元疾病,缺血性损伤,病毒性疾病或真菌感染。

    SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS
    54.
    发明申请
    SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS 审中-公开
    SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES作为KSP抑制剂

    公开(公告)号:US20120070370A1

    公开(公告)日:2012-03-22

    申请号:US13320069

    申请日:2010-05-12

    CPC分类号: C07D513/10

    摘要: The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.

    摘要翻译: 本发明涉及以下式(I)的化合物(其中X,R 1,R 2,R 3,p,环A和环B如本文所定义)。 本发明还涉及包含这些化合物的组合物(包括药学上可接受的组合物),其单独并与一种或多种另外的治疗剂组合,以及其用于抑制KSP驱动蛋白活性的方法,以及用于治疗相关的细胞增殖性疾病或病症 与KSP驱动组织活动。

    Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors
    57.
    发明授权
    Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors 失效
    吡咯并[1,2-a]吡嗪-1,4-二酮丝氨酸蛋白酶抑制剂

    公开(公告)号:US6124291A

    公开(公告)日:2000-09-26

    申请号:US171863

    申请日:1998-10-27

    CPC分类号: C07D487/04

    摘要: This invention relates to pyrrolo[1,2-a]pyrazine-1,4-diones of general formula: ##STR1## wherein B is carbonyl or methylene, R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen, alkyl, or substituted alkyl, A is a basic group, and Q is hydrogen or a keto heterocycle group.The compounds are inhibitors of serine proteases, typically thrombin, Factor Xa, and Factor VIIa, and are useful for treating and preventing thrombotic disorders.

    摘要翻译: PCT No.PCT / US97 / 09832 Sec。 371日期:1998年10月27日第 102(e)日期1998年10月27日PCT 1997年6月10日PCT公布。 公开号WO97 / 48706 日本公开号为1997年12月24日本发明涉及以下通式的吡咯并[1,2-a]吡嗪-1,4-二酮:其中B为羰基或亚甲基,R2,R4,R5和R6为氢,烷基或取代 烷基,A是碱性基团,Q是氢或酮基杂环基。 这些化合物是丝氨酸蛋白酶,通常是凝血酶,因子Xa和因子VIIa的抑制剂,并且可用于治疗和预防血栓形成障碍。